The latest to reach the regulatory stage is teclistamab, one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab.
That alliance also generated Darzalex (daratumumab) – Janssen’s $4.1 billion myeloma blockbuster – as well as Rybrevant (amivantamab), its first bispecific which has been approved to treat EGFR-mutated non-small cell lung cancer (NSCLC).